CN112791090A - 一种用于治疗勃起功能障碍及早泄的组合片 - Google Patents
一种用于治疗勃起功能障碍及早泄的组合片 Download PDFInfo
- Publication number
- CN112791090A CN112791090A CN202110318609.3A CN202110318609A CN112791090A CN 112791090 A CN112791090 A CN 112791090A CN 202110318609 A CN202110318609 A CN 202110318609A CN 112791090 A CN112791090 A CN 112791090A
- Authority
- CN
- China
- Prior art keywords
- food
- erectile dysfunction
- premature ejaculation
- tablet
- treating erectile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010036596 premature ejaculation Diseases 0.000 title claims abstract description 18
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract description 17
- 201000001881 impotence Diseases 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title description 4
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims abstract description 12
- 229960005217 dapoxetine Drugs 0.000 claims abstract description 12
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims abstract description 11
- 229960000835 tadalafil Drugs 0.000 claims abstract description 11
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960004607 alfuzosin Drugs 0.000 claims abstract description 10
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- 239000007884 disintegrant Substances 0.000 claims abstract description 10
- 239000000945 filler Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开的属于医用药品技术领域，具体为一种用于治疗勃起功能障碍及早泄的组合片，以重量份计，其制备原料包含以下组份：他达那非、盐酸达泊西汀、阿夫唑嗪、食品级粘结剂、崩解剂、食品级填充剂，本发明把盐酸达泊西汀装入胶囊，他达那非与阿夫唑嗪压缩在此核周围做成药片，用于治疗勃起功能障碍，早泄以及两症状并存的患者，具有效果好,剂量小，耐受性高，副作用少等特点，具有良好的实用性。
Description
技术领域
本发明涉及医用药品技术领域，具体为一种用于治疗勃起功能障碍及早泄的组合片。
背景技术
早泄属男性功能障碍疾病之一，笼罩着无数的家庭，常可导致夫妻感情不和、不育、甚至离婚。在临床上，他达那非片用于勃起功能障碍的治疗，盐酸达泊西汀片用于早泄的治疗，单独应用效果并不十分理想，尤其是勃起功能障碍合并伴有早泄的患者。
发明内容
本发明的目的在于提供一种用于治疗勃起功能障碍及早泄的组合片，以解决上述背景技术中提出的单独应用效果并不十分理想的问题。
为实现上述目的，本发明提供如下技术方案：一种用于治疗勃起功能障碍及早泄的组合片，以重量份计，其制备原料包含以下组份：他达那非20mg、盐酸达泊西汀30mg、阿夫唑嗪2mg、食品级粘结剂4mg、崩解剂3mg、食品级填充剂40mg。
优选的，所述食品级粘结剂包括食品明胶、甘油、黄原胶、卡拉胶、瓜尔豆胶中的一中或多种。
所述崩解剂包括干淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、交联聚维酮中的一中或多种。
所述食品级填充剂包括淀粉、糖粉、糊精、乳糖、可压性淀粉、微晶限位素、无机盐类、甘露醇中的一中或多种。
其制备方法包括以下步骤：
步骤1：将盐酸达泊西汀装入胶囊中作为片核留作备用；
步骤2：将他达那非、阿夫唑嗪、食品级粘结剂、填充剂与崩解剂进行混合得到药坨，再将药坨均匀压缩在胶囊核心外围，并进行干燥处理后得到药片。
所述步骤2中得到的药片为长椭圆形、圆形、三角形中的一种或多种。
与现有技术相比，本发明的有益效果是：
本发明把盐酸达泊西汀装入胶囊，他达那非与阿夫唑嗪压缩在此核周围做成药片，用于治疗勃起功能障碍，早泄以及两症状并存的患者，具有效果好,剂量小，耐受性高，副作用少等特点，具有良好的实用性。
附图说明
图1为本发明他达那非化学结构式；
图2为本发明达泊西汀化学结构式；
图3为本发明阿夫唑嗪化学结构式。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
在本发明的描述中，需要理解的是，术语“上”、“下”、“前”、“后”、“左”、“右”、“顶”、“底”、“内”、“外”等指示的方位或位置关系为基于附图所示的方位或位置关系，仅是为了便于描述本发明和简化描述，而不是指示或暗示所指的装置或元件必须具有特定的方位、以特定的方位构造和操作，因此不能理解为对本发明的限制。
实施例：
请参阅图1-3，本发明提供一种技术方案：
一种用于治疗勃起功能障碍及早泄的组合片，以重量份计，其制备原料包含以下组份：他达那非20mg、盐酸达泊西汀30mg、阿夫唑嗪2mg、食品级粘结剂4mg、崩解剂3mg、食品级填充剂40mg。
所述食品级粘结剂包括食品明胶、甘油、黄原胶、卡拉胶、瓜尔豆胶中的一中或多种。
所述崩解剂包括干淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、交联聚维酮中的一中或多种。
所述食品级填充剂包括淀粉、糖粉、糊精、乳糖、可压性淀粉、微晶限位素、无机盐类、甘露醇中的一中或多种。
其制备方法包括以下步骤：
步骤1：将盐酸达泊西汀装入胶囊中作为片核留作备用；
步骤2：将他达那非、阿夫唑嗪、食品级粘结剂、填充剂与崩解剂进行混合得到药坨，再将药坨均匀压缩在胶囊核心外围，并进行干燥处理后得到药片。
所述步骤2中得到的药片为长椭圆形、圆形、三角形中的一种或多种。
Claims (6)
1.一种用于治疗勃起功能障碍及早泄的组合片，其特征在于：以重量份计，其制备原料包含以下组份：他达那非20mg、盐酸达泊西汀30mg、阿夫唑嗪2mg、食品级粘结剂4mg、崩解剂3mg、食品级填充剂40mg。
2.根据权利要求1所述的一种用于治疗勃起功能障碍及早泄的组合片，其特征在于：所述食品级粘结剂包括食品明胶、甘油、黄原胶、卡拉胶、瓜尔豆胶中的一中或多种。
3.根据权利要求1所述的一种用于治疗勃起功能障碍及早泄的组合片，其特征在于：所述崩解剂包括干淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、交联聚维酮中的一中或多种。
4.根据权利要求1所述的一种用于治疗勃起功能障碍及早泄的组合片，其特征在于：所述食品级填充剂包括淀粉、糖粉、糊精、乳糖、可压性淀粉、微晶限位素、无机盐类、甘露醇中的一中或多种。
5.根据权利要求1-4任意一项所述的一种用于治疗勃起功能障碍及早泄的组合片，其特征在于：其制备方法包括以下步骤：
步骤1：将盐酸达泊西汀装入胶囊中作为片核留作备用；
步骤2：将他达那非、阿夫唑嗪、食品级粘结剂、食品级填充剂与崩解剂进行混合得到药坨，再将药坨均匀压缩在胶囊核心外围，并进行干燥处理后得到药片。
6.根据权利要求5所述的一种用于治疗勃起功能障碍及早泄的组合片，其特征在于：所述步骤2中得到的药片为长椭圆形、圆形、三角形中的一种或多种。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110318609.3A CN112791090A (zh) | 2021-03-25 | 2021-03-25 | 一种用于治疗勃起功能障碍及早泄的组合片 |
| CN202310241171.2A CN116440091A (zh) | 2021-03-25 | 2021-03-25 | 一种组合片的制备方法及其在药物制备中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110318609.3A CN112791090A (zh) | 2021-03-25 | 2021-03-25 | 一种用于治疗勃起功能障碍及早泄的组合片 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310241171.2A Division CN116440091A (zh) | 2021-03-25 | 2021-03-25 | 一种组合片的制备方法及其在药物制备中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112791090A true CN112791090A (zh) | 2021-05-14 |
Family
ID=75815726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310241171.2A Pending CN116440091A (zh) | 2021-03-25 | 2021-03-25 | 一种组合片的制备方法及其在药物制备中的应用 |
| CN202110318609.3A Pending CN112791090A (zh) | 2021-03-25 | 2021-03-25 | 一种用于治疗勃起功能障碍及早泄的组合片 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310241171.2A Pending CN116440091A (zh) | 2021-03-25 | 2021-03-25 | 一种组合片的制备方法及其在药物制备中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116440091A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389360A (zh) * | 2015-07-31 | 2017-02-15 | 重庆华邦制药有限公司 | 盐酸达泊西汀直压片及其制备方法 |
| CN106511312A (zh) * | 2015-09-11 | 2017-03-22 | 扬子江药业集团江苏紫龙药业有限公司 | 一种复方西地那非达泊西汀缓释胶囊及其制备方法 |
| CN111297869A (zh) * | 2020-04-23 | 2020-06-19 | 白文智 | 一种用于治疗早泄和勃起功能障碍的复方制剂 |
-
2021
- 2021-03-25 CN CN202310241171.2A patent/CN116440091A/zh active Pending
- 2021-03-25 CN CN202110318609.3A patent/CN112791090A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389360A (zh) * | 2015-07-31 | 2017-02-15 | 重庆华邦制药有限公司 | 盐酸达泊西汀直压片及其制备方法 |
| CN106511312A (zh) * | 2015-09-11 | 2017-03-22 | 扬子江药业集团江苏紫龙药业有限公司 | 一种复方西地那非达泊西汀缓释胶囊及其制备方法 |
| CN111297869A (zh) * | 2020-04-23 | 2020-06-19 | 白文智 | 一种用于治疗早泄和勃起功能障碍的复方制剂 |
Non-Patent Citations (4)
| Title |
|---|
| 唐喜等: "早泄药物治疗研究进展", 《内科》, no. 01, 25 February 2011 (2011-02-25) * |
| 程嘉豪等: "慢性前列腺炎/慢性盆腔疼痛综合征伴发性功能障碍的研究进展", 《医学研究生学报》, no. 11, 15 November 2018 (2018-11-15) * |
| 董建军: "他达拉非片联合盐酸达泊西汀治疗原发性早泄的临床效果观察", 《包头医学》, vol. 43, no. 2, 31 December 2019 (2019-12-31), pages 5 - 7 * |
| 陈晓松: "联合应用阿夫唑嗪和西地那非治疗下尿路症状和勃起功能障碍优于单一治疗", 《中国男科学杂志》, vol. 14, 31 January 2008 (2008-01-31), pages 91 - 92 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116440091A (zh) | 2023-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK176018B1 (da) | Formulering med pyridoxin, HC1 og doxylaminsuccinat, dets anvendelse og fremgangsmåde til dets fremstilling | |
| US20190269614A1 (en) | Chewable tablet containing vitamin c sodium and preparation method thereof | |
| CN101703513B (zh) | 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂 | |
| RU2010121135A (ru) | Лекарственные формы для перорального применения, содержащие ацетат ликарбазепина | |
| JP2013544287A (ja) | ランタン化合物を含むカプセル製剤及び粉末製剤 | |
| EP3130334B1 (en) | Controlled-release solid preparation with partial coating | |
| EP1757310A1 (en) | Surface-modified and solubility-improved hard capsule | |
| CN112791090A (zh) | 一种用于治疗勃起功能障碍及早泄的组合片 | |
| JP6479658B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
| CN101152155A (zh) | 盐酸伊伐布雷定固体药物组合物及其制备方法 | |
| CN107213391A (zh) | 一种具有健脾养胃,消食调脂的药物组合物及其制备方法 | |
| CN105012276A (zh) | 一种咪达那新口腔速溶膜及其制备方法和用途 | |
| CN101390844B (zh) | 精氨酸布洛芬片剂及其制备方法 | |
| JP6469234B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
| CN101897709A (zh) | 含有小剂量叶酸和阿司匹林的药物组合物及其用途 | |
| CN205569345U (zh) | 一种芹菜籽提取物软胶囊 | |
| CN101849942B (zh) | 治疗高血压的药物组合物 | |
| CN103720674B (zh) | 法莫替丁漂浮-粘附型微片胶囊及其制备方法 | |
| CN103156817A (zh) | 经口腔粘膜吸收的利扎曲坦药物 | |
| CN107951940B (zh) | 一种降血压药物组合物 | |
| CN101897698A (zh) | 含有维格列汀和b族维生素的降糖药物组合物及其用途 | |
| CN101590040A (zh) | 含有吲哒帕胺和b族维生素的组合物及其用途 | |
| EP1401403B1 (en) | Medicinal compositions comprising a melting core encapsulated in a hydroxypropylmethylcellulose film | |
| CN110179763B (zh) | 一种羟苯磺酸钙分散片及其制备方法 | |
| CN104840480B (zh) | 二甲双胍/叶酸/维生素b12药物组合物的新用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |